ADARx IPO 1.74B aim

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

ADARx Pharmaceuticals seeks a $1.74 billion valuation in its U.S. IPO, aiming to raise $371.9 million while AbbVie secures a 4.9% stake through a concurrent private placement ahead of its Nasdaq listi